Privium Fund Management B.V. Lowers Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Privium Fund Management B.V. reduced its stake in Arrowhead Pharmaceuticals by 2.7%, now holding 612,214 shares valued at approximately $9.85 million.
• Several institutional investors have increased their positions in Arrowhead, with notable growth from Mirae Asset Global Investments, which lifted its stake by 29.5%.
• Research analysts have mixed ratings on Arrowhead Pharmaceuticals, with a consensus rating of Moderate Buy and average price target of $43.14 after recent downgrades and upgrades.

Privium Fund Management B.V. lessened its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 2.7% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 612,214 shares of the biotechnology company's stock after selling 17,000 shares during the quarter. Arrowhead Pharmaceuticals makes up about 2.1% of Privium Fund Management B.V.'s holdings, making the stock its 11th largest position. Privium Fund Management B.V. owned approximately 0.44% of Arrowhead Pharmaceuticals worth $9,851,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the stock. Oak Ridge Investments LLC raised its position in Arrowhead Pharmaceuticals by 2.5% in the 1st quarter. Oak Ridge Investments LLC now owns 33,734 shares of the biotechnology company's stock valued at $430,000 after buying an additional 823 shares during the last quarter. Empowered Funds LLC grew its stake in shares of Arrowhead Pharmaceuticals by 6.9% in the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock worth $194,000 after acquiring an additional 979 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Arrowhead Pharmaceuticals by 9.0% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,476 shares of the biotechnology company's stock valued at $184,000 after purchasing an additional 1,195 shares during the last quarter. KLP Kapitalforvaltning AS raised its holdings in shares of Arrowhead Pharmaceuticals by 5.2% in the second quarter. KLP Kapitalforvaltning AS now owns 24,300 shares of the biotechnology company's stock valued at $384,000 after purchasing an additional 1,200 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Arrowhead Pharmaceuticals by 29.5% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company's stock valued at $84,000 after purchasing an additional 1,214 shares in the last quarter. Institutional investors own 62.61% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ARWR shares. Royal Bank Of Canada reduced their price objective on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. TD Cowen raised Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. Wall Street Zen downgraded Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Finally, B. Riley upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $43.14.

Arrowhead Pharmaceuticals Trading Up 4.5%

NASDAQ:ARWR opened at $38.47 on Tuesday. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $40.29. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. The firm's 50 day moving average is $29.11 and its 200 day moving average is $20.03. The stock has a market capitalization of $5.32 billion, a PE ratio of -30.05 and a beta of 1.13.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The business had revenue of $27.77 million during the quarter, compared to analyst estimates of $29.01 million. During the same period in the prior year, the company earned ($1.38) earnings per share. Sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 20,000 shares of the business's stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total value of $700,000.00. Following the sale, the insider directly owned 212,122 shares in the company, valued at approximately $7,424,270. The trade was a 8.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 60,000 shares of company stock valued at $1,725,000. Insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.